{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:49:10Z","timestamp":1780364950849,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10549-025-07893-2","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:46:53Z","timestamp":1769503613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Second-line treatment strategy following CDK4\/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study"],"prefix":"10.1007","volume":"215","author":[{"given":"Olivia","family":"Lavigne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Poumeaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Reverdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Tuat","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Roces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaulthier","family":"Poupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Gouillou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lique","family":"Bobrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Donadille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Fiteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"7893_CR1","first-page":"203","volume":"7","author":"SR Hosford","year":"2014","unstructured":"Hosford SR, Miller TW (2014) Clinical potential of novel therapeutic targets in breast cancer: CDK4\/6, Src, JAK\/STAT, PARP, HDAC, and PI3K\/AKT\/mTOR pathways. Pharmacogenomics Pers Med 7:203\u2013215","journal-title":"Pharmacogenomics Pers Med"},{"issue":"1","key":"7893_CR2","doi-asserted-by":"publisher","first-page":"e2456142","DOI":"10.1001\/jamanetworkopen.2024.56142","volume":"8","author":"NHY Li","year":"2025","unstructured":"Li NHY, Li CI (2025) Incidence rate trends of breast cancer overall and by molecular subtype by race and ethnicity and age. JAMA Netw Open 8(1):e2456142. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.56142","journal-title":"JAMA Netw Open"},{"issue":"5","key":"7893_CR3","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/annonc\/mdq429","volume":"22","author":"H Roch\u00e9","year":"2011","unstructured":"Roch\u00e9 H, Vahdat LT (2011) Treatment of metastatic breast cancer: second line and beyond. Ann Oncol 22(5):1000\u20131010","journal-title":"Ann Oncol"},{"key":"7893_CR4","doi-asserted-by":"publisher","first-page":"S1384","DOI":"10.1016\/j.annonc.2022.08.009","volume":"33","author":"MP Goetz","year":"2022","unstructured":"Goetz MP, Toi M, Huober J, Sohn J, Tredan O, Park IH et al (2022) LBA15 MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). Ann Oncol 33:S1384","journal-title":"Ann Oncol"},{"issue":"7","key":"7893_CR5","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S et al (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29(7):1541\u20131547","journal-title":"Ann Oncol"},{"issue":"1","key":"7893_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO et al (2015) The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25\u201335","journal-title":"Lancet Oncol"},{"issue":"10226","key":"7893_CR7","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A (2020) Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. The Lancet 395(10226):817\u2013827","journal-title":"The Lancet"},{"issue":"5","key":"7893_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","volume":"28","author":"YS Lu","year":"2022","unstructured":"Lu YS, Im SA, Colleoni M, Franke F, Bardia A, Cardoso F, Harbeck N, Hurvitz S, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, O\u2019Regan R, Gasch C, Solovieff N, Wang C, Wang Y, Chakravartty A, Ji Y, Tripathy D (2022) Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res 28(5):851\u2013859. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3032","journal-title":"Clin Cancer Res"},{"issue":"20","key":"7893_CR9","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N et al (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379(20):1926\u20131936","journal-title":"N Engl J Med"},{"issue":"6","key":"7893_CR10","doi-asserted-by":"publisher","first-page":"100332","DOI":"10.1016\/j.esmoop.2021.100332","volume":"6","author":"E Munzone","year":"2021","unstructured":"Munzone E, Pagan E, Bagnardi V, Montagna E, Cancello G, Dellapasqua S et al (2021) Systematic review and meta-analysis of post-progression outcomes in ER+\/HER2\u2212 metastatic breast cancer after CDK4\/6 inhibitors within randomized clinical trials. ESMO Open 6(6):100332","journal-title":"ESMO Open"},{"issue":"1","key":"7893_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13058-021-01409-8","volume":"23","author":"A DeMichele","year":"2021","unstructured":"DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L et al (2021) Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+\/HER2\u2212 metastatic breast cancer in US real-world clinical practice. Breast Cancer Res 23(1):37","journal-title":"Breast Cancer Res"},{"issue":"5","key":"7893_CR12","first-page":"790","volume":"41","author":"A Bardia","year":"2023","unstructured":"Bardia A, Bonomi M, Modi S et al (2023) Sacituzumab govitecan in metastatic breast cancer with CDH1-expressing tumors: the randomized phase 3 TROPiCS-02 study. J Clin Oncol 41(5):790\u2013799","journal-title":"J Clin Oncol"},{"key":"7893_CR13","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 6.2025."},{"key":"7893_CR14","doi-asserted-by":"crossref","first-page":"e12500","DOI":"10.1200\/JCO.2024.42.16_suppl.e12500","volume":"42","author":"HS Rugo","year":"2024","unstructured":"Rugo HS, Barry WT, Bardia A et al (2024) ASCO guideline update: Management of HR+\/HER2- metastatic breast cancer. J Clin Oncol 42:e12500","journal-title":"J Clin Oncol"},{"issue":"16","key":"7893_CR15","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41388-024-02986-6","volume":"43","author":"A Vasseur","year":"2024","unstructured":"Vasseur A, Cabel L, Hego C, Takka W, Trabelsi Grati O, Renouf B, Lerebours F, Loirat D, Brain E, Cottu P, Sablin MP, Pierga JY, Callens C, Renault S, Bidard FC (2024) Fulvestrant and everolimus efficacy after CDK4\/6 inhibitor: a prospective study with circulating tumor DNA analysis. Oncogene 43(16):1214\u20131222. https:\/\/doi.org\/10.1038\/s41388-024-02986-6","journal-title":"Oncogene"},{"issue":"3","key":"7893_CR16","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/annonc\/mdx784","volume":"29","author":"R Condorelli","year":"2018","unstructured":"Condorelli R, Spring L, O\u2019Shaughnessy J, Lacroix L, Bailleux C, Scott V et al (2018) Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer. Ann Oncol 29(3):640\u2013645","journal-title":"Ann Oncol"},{"issue":"9","key":"7893_CR17","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.bulcan.2021.04.007","volume":"108","author":"F Coussy","year":"2021","unstructured":"Coussy F, Deluche E, Pistilli B, Ladoire S, Ferrero JM, Cottu P (2021) Place des inhibiteurs de kinases d\u00e9pendantes des cyclines 4\/6 dans la prise en charge du cancer du sein avanc\u00e9. Bull Cancer 108(9):843\u2013854","journal-title":"Bull Cancer"},{"issue":"2","key":"7893_CR18","first-page":"171","volume":"2","author":"X Xia-Qing","year":"2021","unstructured":"Xia-Qing X, Pan X-H, Wang T-T, Wang J, Yang B, He Q-J, Ding L (2021) Intrinsic and acquired resistance to CDK4\/6 inhibitors and potential overcoming strategies. Acta Pharmacol Sin 2(2):171\u2013178","journal-title":"Acta Pharmacol Sin"},{"issue":"12","key":"7893_CR19","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A et al (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32(12):1475\u20131495","journal-title":"Ann Oncol"},{"issue":"28","key":"7893_CR20","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F et al (2022) Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol 40(28):3246\u20133256","journal-title":"J Clin Oncol"},{"issue":"23","key":"7893_CR21","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1158\/0008-5472.CAN-23-0694","volume":"83","author":"M Lawson","year":"2023","unstructured":"Lawson M, Cureton N, Ros S, Cheraghchi-Bashi A, Urosevic J, D\u2019Arcy S, Delpuech O, DuPont M, Fisher DI, Gangl ET, Lewis H, Trueman D, Wali N, Williamson SC, Moss J, Montaudon E, Derrien H, Marangoni E, Miragaia RJ, Gagrica S, Morentin-Gutierrez P, Moss TA, Maglennon G, Sutton D, Polanski R, Rosen A, Cairns J, Zhang P, S\u00e1nchez-Guix\u00e9 M, Serra V, Critchlow SE, Scott JS, Lindemann JPO, Barry ST, Klinowska T, Morrow CJ, Carnevalli LS (2023) The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4\/6 inhibitor resistance. Cancer Res 83(23):3989\u20134004. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0694","journal-title":"Cancer Res"},{"issue":"16","key":"7893_CR22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1200\/JCO.2022.40.16_suppl.1021","volume":"40","author":"KL Jhaveri","year":"2022","unstructured":"Jhaveri KL, Jeselsohn R, Lim E, Hamilton EP, Yonemori K, Beck JT et al (2022) A phase 1a\/b trial of imlunestrant (LY3484356) an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC) Monotherapy results from EMBER. J Clin Oncol 40(16):1021","journal-title":"J Clin Oncol"},{"key":"7893_CR23","unstructured":"Johnston S, et al. VERITAC\u20112: Phase III study of vepdegestrant versus fulvestrant in ER\u2011positive, HER2\u2011negative advanced breast cancer with acquired ESR1 mutations. Abstract LBA500, presented at: ASCO Annual Meeting; 2025; Chicago, IL, USA. (Published in J Clin Oncol 2025 ASCO Meeting Proceedings supplement once details are available)."},{"key":"7893_CR24","unstructured":"Turner NC, et al. SERENA\u20116: ctDNA\u2011guided switch to camizestrant plus CDK4\/6 inhibitor in HR\u2011positive, HER2\u2011negative advanced breast cancer with emerging ESR1 mutations. Abstract LBA4, ASCO Annual Meeting 2025; Chicago, IL, USA. (To appear in J Clin Oncol 2025 Meeting). Proceedings)."},{"key":"7893_CR25","doi-asserted-by":"crossref","unstructured":"Bidard F\u2011C, et al. Association between ER, PR and HER2 levels and outcome under palbociclib plus aromatase inhibitors as first\u2011line therapy for ER\u2011positive, HER2\u2011negative metastatic breast cancer: Exploratory analysis of the PADA\u20111 trial (167MO). Ann Oncol. 2022;33(suppl 3):167MO.","DOI":"10.1016\/j.annonc.2022.03.186"},{"key":"7893_CR26","doi-asserted-by":"publisher","first-page":"S388","DOI":"10.1016\/j.annonc.2020.08.452","volume":"31","author":"N Turner","year":"2020","unstructured":"Turner N, Howell S, Jhaveri K, Gomez H, Toi M, Hu X et al (2020) 350TiP A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+\/HER2\u2212 breast cancer (CAPItello-291). Ann Oncol 31:S388\u2013S389","journal-title":"Ann Oncol"},{"key":"7893_CR27","unstructured":"Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial. AstraZeneca. April 29, 2024. Accessed Apr 30 2024"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07893-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07893-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07893-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T09:28:51Z","timestamp":1770802131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07893-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7893"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07893-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"In compliance with French regulations, the database was authorized by the French data protection authority. No formal dedicated informed consent is required but participating centers handle process to ensure that patients are informed about the re-use of their electronically recorded data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"63"}}